University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL

Authors :: Natalie Galanina
Walter M. Stadler
James A. Knost
Kenneth S. Cohen
Bernadette Libao
Theodore Karrison
Austin Doyle
Jason R. Westin
Leo I. Gordon
Chuanhong Liao
Adam M. Petrich
Andrew M. Evens
Sonali M. Smith
Ronald B. Gartenhaus
Source :: British Journal of Haematology. 181:264-267
Publication Year :: 2017
Publisher :: Wiley, 2017.

Subjects :: 0301 basic medicine
Oncology
medicine.medical_specialty
Disease free survival
business.industry
Hematology
Pharmacology
Article
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Tolerability
030220 oncology & carcinogenesis
Internal medicine
medicine
Selumetinib
business
Survival rate

Full Text Access

Tools